Loading...
ILMN logo
ILMN
Illumina

NovaSeq X And SomaLogic Will Drive Precision Medicine Despite Challenges

Published
13 Apr 25
Updated
07 May 25
AnalystHighTarget's Fair Value
US$156.51
41.4% undervalued intrinsic discount
10 Sep
US$91.69
Loading
1Y
-29.5%
7D
-10.8%

Author's Valuation

US$156.51

41.4% undervalued intrinsic discount

AnalystHighTarget Fair Value

Narrative
Updates4

Shared on07 May 25
Fair value Decreased 8.78%

Read more

Shared on30 Apr 25
Fair value Decreased 2.24%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more

Shared on23 Apr 25
Fair value Increased 16%

AnalystHighTarget has increased future PE multiple from 30.5x to 36.5x.

Read more

Shared on16 Apr 25
Fair value Increased 0.19%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more